
Reset all filters
01 11Increlex
Main Therapeutic Indication : Metabolic Disorders
Currency : USD
2020 Revenue in Millions : 23
2019 Revenue in Millions : 26
Growth (%) : -13
Main Therapeutic Indication : Metabolic Disorders
Currency : USD
2021 Revenue in Millions : 19
2020 Revenue in Millions : 23
Growth (%) : -10
Main Therapeutic Indication : Rare Diseases
Currency : USD
2022 Revenue in Millions : 15
2021 Revenue in Millions : 19
Growth (%) : -21
Main Therapeutic Indication : Rare Diseases
Currency : USD
2023 Revenue in Millions : 19
2022 Revenue in Millions : 15
Growth (%) : 24
Main Therapeutic Indication : Rare Diseases and Disorders
Currency : USD
2024 Revenue in Millions : 14
2023 Revenue in Millions : 19
Growth (%) : -24
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2015 Revenue in Millions : 14
2014 Revenue in Millions : 22
Growth (%) : 57%
Main Therapeutic Indication : Metabolic Disorders
Currency : USD
2016 Revenue in Millions : 25
2015 Revenue in Millions : 21
Growth (%) : 20
Main Therapeutic Indication : Metabolic Disorders
Currency : USD
2017 Revenue in Millions : 28
2016 Revenue in Millions : 29
Growth (%) : -3
Main Therapeutic Indication : Metabolic Disorders
Currency : USD
2018 Revenue in Millions : 27
2017 Revenue in Millions : 26
Growth (%) : 5%
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2014 Revenue in Millions : 1%
2013 Revenue in Millions :
Growth (%) :